Jiangsu Hengrui Medicine Co., Ltd.

This phase 3 trial tests a radioactive drug (lutetium-177) combined with standard-dose octreotide against high-dose octreotide alone in 220 adults with advanced gastrointestinal or pancreatic neuroendocrine tumors that cannot be removed by surgery. The goal is to see if the combi…

This phase 3 trial tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one …